Search Results for "Victoza"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Victoza. Results 11 to 20 of 25 total matches.
See also: liraglutide
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012 (Issue 1386)
for injectable suspension 2 mg SC 1x/week 323.44
Liraglutide – Victoza 6 mg/mL (3 mL prefilled pen) 1.2 or 1.8 ...
The FDA has approved a once-weekly extendedrelease
formulation of exenatide (Bydureon – Amylin),
an injectable glucagon-like peptide-1 (GLP-1) receptor
agonist, for treatment of type 2 diabetes.
Lixisenatide for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
, and rarely cause
hypoglycemia.1 The GLP-1 receptor agonist liraglutide
(Victoza) has been shown to reduce ...
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in a
fixed-ratio combination with insulin glargine (Soliqua
100/33). Lixisenatide has been available since 2013 in
many other countries as Lyxumia. It is the fifth GLP-1
receptor agonist to be approved in the US.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
for cardiovascular disease, addition of
liraglutide (Victoza) to standard therapy significantly
reduced ...
...
A Renal Indication for Semaglutide (Ozempic)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
risk factors
Exenatide1
▶ Treatment of type 2 diabetes in adults
Liraglutide (Victoza, and generics ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Ozempic – Novo
Nordisk) has been approved by the FDA to reduce
the risk of sustained eGFR decline, end-stage kidney
disease, and cardiovascular death in adults with
type 2 diabetes and chronic kidney disease (CKD). It is
the first GLP-1 receptor agonist to be approved in the
US for this indication.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):38-40 doi:10.58347/tml.2025.1723d | Show Introduction Hide Introduction
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
suspension3
Bydureon BCise 2 mg single-dose autoinjector3 2 mg SC once/wk4,6 660.20
Liraglutide – Victoza ...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013 (Issue 1416)
cause weight loss, Must be injected, nausea, 350.00
Liraglutide – Victoza Bydureon is once-weekly ...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
%
▪ Liraglutide is also available as Victoza (SC injection) for
treatment of type 2 diabetes in patients >10 ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2 doi:10.58347/tml.2024.1708d | Show Introduction Hide Introduction
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
– Victoza (Novo Nordisk) 6 mg/mL (3 mL prefilled pen) 1.2 or 1.8 mg SC once/d4 537.80
Insulin degludec ...
The FDA has approved Xultophy 100/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin
degludec and the GLP-1 (glucagon-like peptide-1)
receptor agonist liraglutide, for once-daily treatment
of adults with type 2 diabetes inadequately controlled
on basal insulin (<50 units daily) or liraglutide (≤1.8
mg daily).
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
in
patients with type 2 diabetes, the selective GLP-1
receptor agonists liraglutide (Victoza), semaglutide ...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
Liraglutide – Victoza (Novo Nordisk)2 6 mg/mL (3 mL) prefilled pens 1.2 or 1.8 mg SC once/day6 614.50 ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.